Antidepressant selection, healthcare resource consumption and costs in a large workplace environment: US and Canadian perspectives

Clinical Drug Investigation

Volumn 22, Issue 10, 2002, Pages 685-694

  Optenberg, Scott A ^a   Lanctôt, Krista L ^b,c   Herrmann, Nathan ^b,c,d   Oh, Paul I ^b,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; HYPNOTIC AGENT; IMIPRAMINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CANADA; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE CLASSIFICATION; DRUG COST; DRUG TOLERABILITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT PLANNING; UNITED STATES; WORKER; WORKPLACE;

EID: 0036394291     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222100-00005     Document Type: Article

References (39)

1. Scott AI, Freeman CP. Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. BMJ 1992; 304 (6831): 883-7
2. Eaton WW, Kramer M, Anthony JC, et al. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1989; 79 (2): 163-78
3. Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins LN, Regier DA, et al. editors. Psychiatric disorders in America: the epidemiologics catchment area study. New York: Free Press, 1991: 53-80
4. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50 (2): 85-94
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51 (1): 8-19
6. Patten SB. Incidence of major depression in Canada. CMAJ 2000; 163 (6): 714-5
7. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262 (7): 914-9
8. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264 (19): 2524-8
9. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267 (11): 1478-83
10. Revicki DA, Turner R, Brown R, et al. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Qual Life Res 1992; 1 (4): 257-66
11. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8 (6): 387-94
12. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405-18
13. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7 (3-4): 191-5
14. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36
15. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6 (1): 10-8
16. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159 (10): 1245-52
17. Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999; 175: 120-6
18. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999; 100 (3): 193-8
19. Liebowitz MR. Update on the diagnosis and treatment of social anxiety disorder. J Clin Psychiatry 1999; 60 Suppl. 18: 22-6
20. Sheehan DV. Current concepts in the treatment of panic disorder. J Clin Psychiatry 1999; 60 Suppl. 18: 16-21
21. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60 (2): 101-6
22. Dunner D, Kumar R. Paroxetine: a review of clinical experience. Pharmacopsychiatry 1998; 31 (3): 89-101
23. Ravindran AV, Judge R, Hunter BN, et al. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 1997; 58 (3): 112-8
24. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164 (5): 665-73
25. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990, 1
26. Pearson SD, Katzelnick DJ, Simon GE, et al. Depression among high utilizers of medical care. J Gen Intern Med 1999; 14 (8): 461-8
27. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38 (2-3): 97-111
28. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16 (4): 715-30
29. Skaer TL, Sclar DA, Robison L. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995; 56 (6): 556-7
30. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71-9
31. Nurnberg HG, Hensley PL, Thompson PM, et al. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors. Psychiatr Serv 1999; 50 (10): 1351-3
32. Melton ST, Kirkwood CK, Farrar TW, et al. Economic evaluation of paroxetine and imipramine in depressed outpatients. Psychopharmacol Bull 1997; 33 (1): 93-100
33. Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158 (12): 1989-92
34. Chouinard G, Saxena B, Belanger MC, et al. A Canadian multi-center, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999; 54 (1-2): 39-48
35. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286 (23): 2947-55
36. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57 (4): 507-33
37. Greenfield S. The state of outcome research: are we on target? N Engl J Med 1989; 320 (17): 1142-3
38. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med 1991; 115 (11): 901-5
39. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48 (3): 363-73